Collectively, our results highlight the beneficial effects of GRASPtreatment and its potential for future use as a novel treatment ofchemotherapy-induced malaise and potentially other conditions associatedwith uncontrolled nausea and vomiting due to elevated GDF15 levels(e.g., hyperemesis gravidarum). This evidence concerns the gene GDF15 and hyperemesis gravidarum.